Fig 1.
Participant flow diagram.
Table 1.
Total cohort demographic, renal, and prescribing parameters (n = 2,046).
Fig 2.
Flowchart showing the classification algorithm used to identify participants as either MASLD with fibrosis (left) or MASLD without fibrosis (right).
Table 2.
Fibrosis biomarker results for the cohort (n = 2,046).
Table 3.
Models of relative risk of chronic kidney disease among those with MASLD fibrosis, both univariable and adjusted for confounders (n = 2,024).
Fig 3.
Kaplan-Meier survival curve demonstrating impaired survival according to MASLD fibrosis and CKD status, adjusted for age, sex, cardiovascular disease, and diabetes (n = 2,024).
Note: Red dotted line on X axis denotes earliest entry age to the analysis (i.e. youngest age at date of screening). This analysis excluded individuals with CKD of structural, autoimmune, or malignant, aetiology; therefore, n = 7 deaths are excluded from the estimates.
Table 4.
Cox models of mortality risk among those with MASLD and CKD, both univariable and adjusted for confounders (n = 2,024).